Coverage
Filings
| Filing | Date |
|---|---|
| Director/PDMR Shareholding | 12 Jun 2024 |
| Statement: Zantac (ranitidine) litigation | 11 Jun 2024 |
| FDA approves Arexvy for adults 50-59 at risk | 10 Jun 2024 |
| Statement: Zantac (ranitidine) litigation | 10 Jun 2024 |
| Statement: Zantac (ranitidine) litigation | 3 Jun 2024 |
| ASCO positive Blenrep DREAMM-8 trial results | 3 Jun 2024 |
| Unprecedented results in Jemperli trial continue | 3 Jun 2024 |
| Total Voting Rights |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 3 Jun 2024 |
| Statement: Zantac (ranitidine) litigation | 24 May 2024 |
| Positive phase III asthma results for depemokimab | 21 May 2024 |
| Director/PDMR Shareholding | 20 May 2024 |
| GSK completes sale of shares in Haleon plc | 17 May 2024 |